Evidence map›Paper›PMID 41615553›Full record

ReviewCell biochemistry and biophysics2026

Induced Pluripotent Stem Cells (iPSCs) as a Regenerative Strategy for Parkinson's Disease: Opportunities and Challenges.

Ahmad Faried, Reno Rudiman, Achmad Adam, Djaja Rusmana, Rizal Azis, Hanna Sari Widya Kusuma, Aris Muhamad Nurjamil, Wahyu Widowati

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmad FariedDepartment of Neurosurgery, RS UNPAD University Hospital, Jatinangor, Indonesia. ahmad.faried@unpad.ac.id.ORCID http://orcid.org/0000-0003-2967-8125
Reno Rudiman *Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Achmad Adam *Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Djaja RusmanaFaculty of Medicine, Maranatha Christian University, Bandung, Indonesia.
Rizal AzisBiomedical Engineering, Department of Electrical Engineering, Faculty of Engineering, Universitas Indonesia, Depok, Indonesia.
Hanna Sari Widya KusumaBiomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung, Indonesia.
Aris Muhamad NurjamilBiomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung, Indonesia.
Wahyu WidowatiDepartment of Pharmacology, Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson’s disease (PD) is a chronic and progressively debilitating neurodegenerative condition marked by the gradual depletion of dopaminergic neurons within the substantia nigra. This neuronal loss manifests as a spectrum of motor dysfunctions and non-motor disturbances that profoundly affect daily functioning and overall quality of life. Current clinical interventions, including levodopa administration and deep brain stimulation, largely target symptom management rather than addressing the underlying neurodegenerative processes, thereby offering only temporary relief. In light of these limitations, there has been growing interest in regenerative approaches aimed at restoring neuronal function. Among these, induced pluripotent stem cells (iPSCs) have revolutionized the field, enabling the reprogramming of patient-derived somatic cells into pluripotent states that can subsequently be differentiated into functional dopaminergic neurons. Beyond their therapeutic potential for cell replacement, iPSCs also provide an invaluable platform for modeling disease mechanisms and evaluating novel treatment strategies. iPSCs enable patient-specific disease modelling and physiologically relevant drug screening. Preclinical evidence demonstrates that transplantation of iPSC-derived dopaminergic neurons can restore motor function, while support the feasibility and short-term safety. Nevertheless, significant challenges remain, including tumorigenicity risk, differentiation variability, graft integration challenges, and economic, regulatory, and ethical issues. With the advancement of innovations including gene editing, brain organoids, and multimodal approaches, iPSCs hold great promise to revolutionize Parkinson’s therapy toward safer, more effective, and personalized precision medicine. Unlike previous reviews, this article integrates mechanistic insights, translational barriers, and future technological directions, offering a focused perspective on how iPSC-based strategies may be realistically advanced toward clinical application.

Indexed as

Induced Pluripotent Stem CellsParkinson DiseaseAnimalsCell DifferentiationDopaminergic NeuronsHumansDopaminergic neuronsInduced pluripotent stem cellsParkinson’s diseasePrecision medicineRegenerative therapy

Identifiers

PMID41615553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.